CO078 | METABOLOMIC AND LIPOPROTEOMIC MODULATION FOLLOWING INCLISIRAN TREATMENT IN DYSLIPIDEMIC PATIENTS
Background and Aims. Inclisiran is a subcutaneously administrated synthetic small interfering RNA directed against proprotein convertase subtilisin–kexin type 9, leading to sustained low-density lipoprotein cholesterol (LDL-C) reduction with a twice-yearly dosing regimen. While its lipid-lowering efficacy is well estab...